Siludi Medicine
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Siludi Medicine - overview
Established
2017
Location
Shanghai, Shanghai, China
Primary Industry
Pharmaceuticals
About
Based in Shanghai, China, and established in 2017, Siludi Medicine operates as a biopharmaceutical company that focuses on tumor immunotherapy drug development. The company was split from 3D Medicines Corporation due to business development needs. In October 2020, Siludi Medicine raised a series A funding for CNY 970 million from new investors Efung Capital, China Capital Management, Tigermed, and Haide Venture Capital. Siludi Medicine's main business is the research, development, and commercialization of tumor immunotherapy drugs.
Its current pipeline consists of two clinical-stage drug candidates, including KN035, a subcutaneously administered PD-L1 antibody, and 3D-185, a selective FGFR-1/2/3 inhibitor. The KN035 was approved for clinical studies by FDA/NMPA/PMDA in 2017. The company will use the funding used for product line expansion, clinical trial advancement, industry chain layout, and team recruitment.
Current Investors
Efung Capital, China Capital Management, Tigermed
Primary Industry
Pharmaceuticals
Sub Industries
Oncology/Cancer Treatment, Specialty Pharmaceuticals
Company Stage
Series A
Total Amount Raised
Subscriber access only
Siludi Medicine - key contacts
| Name | Position | Start Date | End Date | Vcard | Bio | ||
|---|---|---|---|---|---|---|---|
| Chief Executive Officer & General Manager | BM |
BM Board Member
Want to see more?
Request a demo for full access to this profile
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.